Humana Cuts FY21 Earnings Outlook Reflecting Net COVID Headwind

Loading...
Loading...
  • Humana Inc HUM posts Q3 sales of $20.87 billion, missing the consensus of $20.91 billion. 3Q21 and YTD 2021 results reflect the continued impact of the COVID-19 pandemic.
  • The benefits expense ratio increased from 85.3% to 87.1%, while the operating cost ratio declined from 13.2% to 12.2%. The Operating cash flow reached $2.83 billion.
  • Humana posted an adjusted EPS of $4.83, beating the consensus of $4.66.
  • As a result of the surge in COVID cases due to the Delta variant, Humana expects non-COVID Medicare Advantage utilization of 5.5% below baseline in the back of the year while being partially offset by 3% of COVID costs, therefore, again assuming total utilization would be 2.5% below baseline in 2H of FY21.
  • Guidance: Humana is revising its FY21 GAAP EPS guidance to approximately $23.67 from the prior outlook of $24.97 - $25.47.
  • The Company is also revising its FY21 Adjusted EPS guidance to approximately $20.50 from $21.25 - $21.75. 
  • The current FY21 EPS guidance reflects the Company’s updated view of utilization for Q4 of 2021.
  • Updates FY 2021 expected individual Medicare Advantage membership growth to 450,000 members, +11% Y/Y down from previous guidance of 425,000 - 475,000.
  • Price Action: HUM shares closed at $457.11 on Tuesday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...